Overview

Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer

Status:
Unknown status

Trial end date:
2019-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the efficacy and safety of patients who receive apatinib single or combined capecitabine for treatment of patients with metastatic her-2 negative breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Hebei Medical University Fourth Hospital

Treatments:

Apatinib
Capecitabine